Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SON is a large nuclear speckle-associated protein encoded by the SON gene, characterized by both DNA- and RNA-binding domains and multiple splicing-related motifs[1][2][3][4]. Functionally, it is an essential splicing co-factor that facilitates the efficient splicing and correct processing of weak splice sites, particularly in genes involved in the cell cycle, DNA repair, and genome maintenance[2][3][4]. SON is required for proper mitosis, chromosome alignment, genome stability, and centriole assembly, and its deficiency can cause severe developmental and cellular defects[1][2][3]. Mutations or aberrant isoform expression of SON are implicated in neurodevelopmental syndromes (such as ZTTK syndrome), glioblastoma, hematologic malignancies (like myelodysplastic syndromes and acute myeloid leukemia), and possibly other cancers, in part due to its role in regulating the splicing and expression of oncogenes and tumor suppressors[1][3][4][6]. SON is not classified as a classic therapeutic target (e.g., receptor, enzyme, transporter) but is a critical nuclear factor influencing RNA metabolism and genome stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SON DNA- and RNA-binding protein (SON).